| 应用 | Usually used as photosensitizer to investigate the photoisomerization of trans-stilbene (TS) in sodium dodecyl sulfate (SDS)/benzyl alcohol (BA)/H2O system. |
| 别名 | 9,10-二氰蒽；蒽-9,10-二腈;Anthracene-9,10-dicarbonitrile |
9,10-二氰基蒽
9,10-Dicyanoanthracene （订货以英文为准）
编号：D155097
CAS号：1217-45-4
分子式：C16H8N2
分子量：228.25
| 产品名称 | 9,10-Dicyanoanthracene |
| 中文名称 | 9,10-二氰基蒽 |
| CAS号 | 1217-45-4 |
| 分子式（M.F.） | C16H8N2 |
| 分子量（M.W.） | 228.25 |
技术规格
| Background: | NF-kappa-B is a pleiotropic transcription factor which is present in almost all cell types and is involved in many biological processed such as inflammation, immunity, differentiation, cell growth, tumorigenesis and apoptosis. NF-kappa-B is a homo- or heterodimeric complex formed by the Rel-like domain-containing proteins RELA/p65, RELB, NFKB1/p105, NFKB1/p50, REL and NFKB2/p52 and the heterodimeric p65-p50 complex appears to be most abundant one. The dimers bind at kappa-B sites in the DNA of their target genes and the individual dimers have distinct preferences for different kappa-B sites that they can bind with distinguishable affinity and specificity. NF-kappa-B complexes are held in the cytoplasm in an inactive state complexed with members of the NF-kappa-B inhibitor (I-kappa-B) family. In a conventional activation pathway, I-kappa-B is phosphorylated by I-kappa-B kinases (IKKs) in response to different activators, subsequently degraded thus liberating the active NF-kappa-B heterodimeric p65-p50 and p65-c-Rel complexes are transcriptional activators. The inhibitory effect of I-kappa-B upon NF-kappa-B the cytoplasm is exerted primarily through the interaction with p65. p65 shows a weak DNA-binding site which could contribute directly to DNA binding in the NF-kappa-B complex. |
| Applications: | WB, IHC, IF |
| Name of antibody: | RELA (Phospho-Ser529) |
| Immunogen: | Synthetic peptide of human RELA (Phospho-Ser529) |
| Full name: | v-rel reticuloendotheliosis viral oncogene homolog A (avian) (Phospho-Ser529) |
| Synonyms: | p65; NFKB3 |
| SwissProt: | Q04206 |
| IHC positive control: | Human breast carcinoma |
| IHC Recommend dilution: | 50-100 |
| WB Predicted band size: | 65 kDa |
| WB Positive control: | 293 cells untreated or treated with TNF-α |
| WB Recommended dilution: | 500-1000 |
| Positive control: | Hela cells |
| Recommended dilution: | 100-200 |
搜索质检报告(COA)
搜索MSDS
相关产品
¥ 400.00
CYD-014U -1袋
¥ 39600.00
CB58180967
¥ 4530.00
shsc-006-06-10L
¥ 3500.00
A909343-1g
党沛 
